FDA Approves Gavreto (pralsetinib) for the Treatment of Advanced NSCLC with Tumors Having Changes in RET
On September 4th, 2020, the Food and Drug Administration (FDA) approved Gavreto (pralsetinib) for the treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in RET. The FDA based their approval on the results of the [...]